{"name":"Stallergenes Greer","slug":"stallergenes-greer","ticker":"","exchange":"","domain":"","description":"Stallergenes Greer International AG is a Swiss biopharmaceutical company specializing in the diagnosis and treatment of allergies through allergen immunotherapy.","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"300 IR","genericName":"300 IR","slug":"300-ir","indication":"Other","status":"marketed"},{"name":"Oralair","genericName":"Oralair","slug":"oralair","indication":"Other","status":"marketed"},{"name":"Staloral","genericName":"Staloral","slug":"staloral","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"300 IR","genericName":"300 IR","slug":"300-ir","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Oralair","genericName":"Oralair","slug":"oralair","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Staloral","genericName":"Staloral","slug":"staloral","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPSHJKY2ZtdlMzbUNKY1VnQ2hYVzZOWnFmZGpXTk9qRmZkODZMa05sSXVIc2hxMGRlYXM4WmY1NGw1RWpuMmNqTVgtbFk4WUxfZkIwaUI2MjVWUC1COHhoeFNUQ1lqS2wwUWpsR0JIYnNsVUdjWkEyU19uUTE4ck5qWFpVM29TU3c5X2JyZGNFaHNRLUlYclR5QVRYMVlNSS03YWFpV1hpVjlpbUJ4RmpqLVg0U3AwbDY1LXB5SThsaEV3Xy1KT0JKbW9wNEhFUFJhUk1iMlgxeVlfZ2NTbHk3MG5tOTVtOXh4WEc5a3d5cw?oc=5","date":"2026-01-07","type":"pipeline","source":"Business Wire","summary":"Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l. - Business Wire","headline":"Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPVEJJSm52TF9UZGVEV3JtUkEtS1ZiTXBQS2dZWjhlZ1lfUlZxTnRqZXZWU281YkJ1SXVtRTIyaEpNbUVpOHIwNW5nX09UYzBYdU1vQ2o2ZDhCUnBIUGJNRUNRQzZXOU1yU1JkX1pPaUowbk9BamREajZxN0RqQXA1bUI5QVk2WGk3TEE?oc=5","date":"2025-12-17","type":"pipeline","source":"pharmaphorum","summary":"DBV gets peanut allergy therapy programme back on track - pharmaphorum","headline":"DBV gets peanut allergy therapy programme back on track","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE1oRXZMbWNfZGFHVjVYUWVpU04yT2E5X0dVSzloSThqSkM5LUNKQ0xwTzZjc0hzWE9ubmZ4RVRJRXV3Qk5RQ2cwQTBON3RwNkZTRlhyV21SY3ZKVHhVOUExT3BZSUtiZHlwNTNQNjlLNA?oc=5","date":"2025-11-19","type":"pipeline","source":"medwatch.com","summary":"Nordic manager for Stallergenes Greer resigns after two years - medwatch.com","headline":"Nordic manager for Stallergenes Greer resigns after two years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxPSG5YRXZJMi0zbUlJZkNKZzVFVjVIb0lQSlVmZDlhWnc1a291VEJiWUFKWHNOMW5hckNKVmtJQXlvNWxvU3E3YnROcGRTRkNhbExNXzlWb0pFU0ZBeXZwdURkeXZFZ2JiUDBmQWtpUnJmamZiNWFCTEstb0puVmRiRWhHYXgyaXhBNnQxWGpyXzVSTl94Q3NiMm9rbGZCX2lJMHJud1ZheTRsY3hqTmU3OXEzSTFvb1BvTXh5Wm14bS1TZ3NFdXAxdlg4Y2o0SXppVGR5azkxTFk2TXFTZ0Iwa3ctaDl2UGVTM2YyM0NWVlVBemM0aVdWVDhoYVNza0x1c0IzemY4NFh3YmtiVV9Xa19JNmpyb2hXZ3pDXzg0TkdneU9OV1hic0lCN3IzMnNZUzlBRk1VM25RdjVFZGdnWXM3cDJMM2VVN09lQg?oc=5","date":"2025-09-03","type":"deal","source":"Business Wire","summary":"Stallergenes Greer and Nuance Pharma Enter Exclusive Long-term Partnership for Actair - Business Wire","headline":"Stallergenes Greer and Nuance Pharma Enter Exclusive Long-term Partnership for Actair","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNc3hCbXhfczFYMWpaYVB3TFlsNE4yeGNTMDhKUTlaR1BFNEdwTVBlaVhkMDNLWjRKOXdoN1RCY0x0SFlEaFBJbHJObUJLSFVyaE9LTnJ3QTNHaW42SXU5am15UTUwMjdRdmRaOVdIbmhyU3Nyc3RvS2stcWtaSkxHZnRERklCTmxNZ3Y4clFkOUdXUQ?oc=5","date":"2025-02-10","type":"pipeline","source":"Future Market Insights","summary":"Allergy Immunotherapy Market Trends & Competitive Outlook - Future Market Insights","headline":"Allergy Immunotherapy Market Trends & Competitive Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOejE3MlZCUURJOFEySUgyRG96bF8ydG9UeWptb2NOOG5fQXVRdHJJNnJJVWRTdGhKT2hONEc1Sm41Y2N1dmczZHliVHJrMU1KU2JjajdIaGtFbktBcjJHWGhscFVwYWJOcDZMcXd6YTZCQXc5ZGNma1hiLUpfaV9PWGpmRzZRSWlNejVpRlVfbnVFT0EzTmFEbTFjV014a3B6SDdJ?oc=5","date":"2023-10-24","type":"pipeline","source":"Aptar","summary":"Aptar Digital Health Announces Stallergenes Greer iPUMP®Launch - Aptar","headline":"Aptar Digital Health Announces Stallergenes Greer iPUMP®Launch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPY3lEMUVXSGprci1qZHMtV0lqOWV5ajJtcHU4VmVBTTFPdS1lTmd5bWlzNDVVQWNUQURFNUJlR3g4WHNRZGdTaVhVSFN4S3RFUnhKQTFyZ0VkRDZTSERsS2R2SHJoQTYtVUNnWUhaSWFidGcyWXVYd1lnd1Bya1pqQVBTRVBYOHhkaVFQT2w2WDJLN1QxUkFwQjB1OTdONjBzQVlqdkdkbmo0bFdjQ2R6ZGo0Q2lZY0lpdF9N?oc=5","date":"2023-09-05","type":"pipeline","source":"Pharmaceutical Technology","summary":"Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer - Pharmaceutical Technology","headline":"Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOZk9HQ1NqQ1N3S2p5bDBwV3B0Tm1NY3Y5S2hnUDNaUTF3UzJ5VXN1R1BrVDIwMmJHeHFrbVlHUHl6cUwtMUJfLS1mYmp1VmRTUHRNR1o2akJ2bmlQcEF4TjFxSmEyQV9RVXdnWjNTV0RvTUozSFUtcjY2Yk9LMkpWZmc2Qjdua1BwTUZTcDdBUQ?oc=5","date":"2023-09-05","type":"pipeline","source":"BioPharma Dive","summary":"Nestle gives up on peanut allergy treatment after sluggish sales - BioPharma Dive","headline":"Nestle gives up on peanut allergy treatment after sluggish sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOMkhJMV9UYjdlM2JkTHgwZG5JMmtDSkJxeTRIdHdaZFo3TjdMc1ExelpEdjZFbTNGLThONTBOeW1TenJRZElXSGUxUXhfRFNuQWhVYWo5bEFlNGNjbHdiRy1NNFROQTBvSjZ6S3VCRW9xOGRxT0Vaa1REb2V5OXBPTUNNQ1JfNXlCOVNldUVFVUZkTWFQX3ZRV1VhbjBWMm1aN0EwbHBRcHYzU0dGS1dn?oc=5","date":"2023-09-05","type":"deal","source":"Fierce Pharma","summary":"Years after $2B buyout, Nestlé ditches Aimmune's peanut allergy drug Palforzia - Fierce Pharma","headline":"Years after $2B buyout, Nestlé ditches Aimmune's peanut allergy drug Palforzia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPVWVFazZhX1ZZVHZWSUl1amRVeHVlOWZicUZ6UDlBRUllRTZ0V1I3NWlZTHpwazQ1THN5SmtidnFMcVpGUEJ0VlFaSjN0bWtHTmYzd1ZvZWZTN0RPRTNhbGNHdHoxMGs1bkdyeEoycURnaU9mdnlJUHVBcmtFUFRpNS1uSms4S1JNNjNwYnl4ZmNqX1hWRFFKODM1R3p4cktSUGdHS3JNM3FJdEtNVUkxenh5NzVINHMydFEyZTB5VTUzbDlfVWZIMU5FaTlMQ2VORDZkZDJzV2ZTR1ZXNXV4R01JRDFBMjRRc1V0a29ySlBjUQ?oc=5","date":"2021-10-26","type":"pipeline","source":"Aptar","summary":"Aptar Pharma and Stallergenes Greer Work on Digital Solutions for AIT - Aptar","headline":"Aptar Pharma and Stallergenes Greer Work on Digital Solutions for AIT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNYVZTQTdwV2RYY2laenE0WV9nb1ROdlFscUVsdnd1VVBXbnpCMURPOUJPV2RFcDNmVHh4aUVuU2VkUlpBeWxDaG9welFfZ1pnZlVtamlmUUF3UHFEUFNwdzN0b0ZHRVBkOFNLNkN5S2UxUW9wb2J2R05KVFlRazUtMlBmTE5qVFhoQWRmT1Q0aWQ4T21pLXpHYXk3WjBmU1FBM3lzM1NFOTNCTm9XX2l3cVlsNkRnSk5iTEljeg?oc=5","date":"2021-06-01","type":"pipeline","source":"Fierce Pharma","summary":"Stallergenes Greer gets positive opinion for sublingual allergy immunotherapy - Fierce Pharma","headline":"Stallergenes Greer gets positive opinion for sublingual allergy immunotherapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRnBRNEJUR0xZNjF0bWtPYllrNnVtckUxdEIyaFh3QUJic19aY3dORFd6ZC1tR0ZNYWZzSHZ1Yk42NEFLanVTdDBlYm5hdjhTWW85a09fclM1NlpoVFp0ek02V3Jid09RQ08yMENJdVB5LURmbXJjVTBnY1lUeVVwaldsb2tvSzk5N3NDYXZscnRwMVJITDFwQzFnSmwtWG5XdjBnYVhPd2xQbkU?oc=5","date":"2016-02-02","type":"pipeline","source":"The Pharma Letter","summary":"Stallergenes Greer able to resume manufacturing at Antony plant - The Pharma Letter","headline":"Stallergenes Greer able to resume manufacturing at Antony plant","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":2,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}